samedan logo
 
 
 
spacer
home > ebr > summer 2004 > the declaration of helsinki: protecting patient rights in biomedical research drug discovery technologies
PUBLICATIONS
European Biopharmaceutical Review

The Declaration of Helsinki: Protecting Patient Rights in Biomedical Research Drug Discovery Technologies

The Declaration of Helsinki is the world's most widely recognised source of ethical guidance for biomedical research. Since its adoption in 1964, it has become the pre-eminent ethical guidance on health care research. Adherence to it is required by the World Health Organization and by many national governments, who refer to its provisions in their legislation. Scientists are often criticised for carrying out research in developing countries without following the Declaration, and some organisations and companies sponsoring research request that researchers receiving funding abide by its requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Delon Human, Secretary General of the World Medical Association

Dr Delon Human has been Secretary General of the WMA since 1998. He is a former family physician from Pretoria, South Africa and a past president of a branch of the Medical Association of South Africa. He qualified as a family practitioner in 1985 and spent some time at the John Radcliffe Hospital in Oxford, England, conducting research in paediatric endocrinology. He then gained two further Masters degrees in Family Medicine and a Diploma in Child Health. In addition to his medical qualifications, Dr Human has also obtained an MBA from the European Business School.

spacer
Dr Delon Human
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLIŽ (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLIŽ (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement